Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Oxalys from Brussel, company number BE0451435822, closed financial year 2025 with a result of € -12,503 after tax. For that financial year Oxalys recorded revenue of € 122,594 and equity of € 178,408. Compared with financial year 2024, the result moved from € -19,076 to € -12,503. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 178,408
▼ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -12,503
▲ 34 % less loss than in 2024
Profit after tax over the fiscal year.
€ 174,475
▼ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 177,355
▲ 1% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 9,597
▼ 58% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 35,832
▲ 32% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 81,502 | € 111,746 | € 90,406 | € 122,594 | ▲ 36% |
| Gross margin | € 169,103 | € 181,401 | € 166,971 | € 171,095 | ▲ 2% |
| Profit after taxes | € -10,290 | € 2,626 | € -19,076 | € -12,503 | ▲ € 6,573 |
| Equity | € 207,361 | € 209,987 | € 190,911 | € 178,408 | ▼ 7% |
| Total debts | € 52,815 | € 53,089 | € 50,269 | € 45,429 | ▼ 10% |
| Cash | € 192,051 | € 198,098 | € 179,533 | € 174,475 | ▼ 3% |
| Retained profit | € 207,361 | € 209,987 | € 190,911 | € 178,408 | ▼ 7% |
| Balance sheet total | € 260,176 | € 263,076 | € 241,180 | € 223,837 | ▼ 7% |
Key figures of Oxalys, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Oxalys?
What happened at Oxalys in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 12,503. Source: NBB ↗
- Sofie Bultinck became a director. NBB
- Toon Fret became a director. NBB
- Bert Anciaux stepped down as director. NBB
- Bart Caron stepped down as director. NBB
- Shirley Laub stepped down as director. NBB
- Michel Defloor stepped down as director. NBB
- Lies Martens stepped down as director. NBB
In short
From € 10,290 loss in 2022 to € 12,503 loss in 2025.
Best year ever: 2023, with € 2,626 profit.
A new publication or filing at Oxalys? We notify you, reason included.
Follow OxalysDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Oxalys are Sofie Bultinck, Toon Fret and Piet Van Bockstal.
Directors
According to the 2025 annual accounts
Sofie Bultinck
Director
since 2023
Toon Fret
Director
since 2023
Piet Van Bockstal
Director
since 2019
Shirley Laub
Director
since 2019 · until 2022
since 2019 · until 2022
Bert Anciaux
Director
Also active at: De Overbron, Brik - Student in Brussel, BAN LAW AND CONSULT-ADVOCATENKANTOOR BERT ANCIAUX, Caisse de Retraite des Sénateurs
since 2020 · until 2023
Bart Caron
Director
Also active at: De Vlaamse Radio- en Televisieomroeporganisatie, KAAP, Unie der Zorgelozen, DEMOS, meemoo, Vlaams instituut voor het archief, HISTORIES
since 2020 · until 2023
Lies Martens
Director
since 2019 · until 2022
since 2019 · until 2022
Peter Swinnen
Director
since 2019 · until 2022
Kathleen Coessens
Director
Also active at: Concours Musical International Reine Elisabeth de Belgique
since 2019 · until 2022
Séverine Provost
Director
since 2019 · until 2022
Jos Stassen
Director
since 2019 · until 2022
Establishments
Establishment units
Physical locations of this company
Masuiplein 13
1000 Brussel
Masuiplein 13
1030 Schaarbeek
Active since 21 December 2006
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0451.435.822
- VAT number
- BE 0451.435.822
- Registered office
- Masuiplein 13, 1000 Brussel
- Names & denominations
- Oxalys
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 8 July 1993
- Peppol
- Active · Active since 29 Dec 2025
- Activities · NACE
Beoefening van uitvoerende kunsten door artistieke ensembles
Gespecialiseerde beeld-, verlichtings- en geluidstechnieken